Interleukin 17 in early invasive breast cancer

Znanstveni rad - Izvorni znanstveni rad

• Autor: Marina Popović
• Autor: Natalija Dedić Plavetić
• Autor: Damir Vrbanec
• Autor: Zlatko Marušić
• Autor: Davor Mijatović
• Autor: Ana Kulić
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA INTERNU MEDICINU)
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA KIRURGIJU)
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA PATOFIZIOLOGIJU)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Patofiziologija
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Kirurgija
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Interna medicina

Sažetak (engleski)

Introduction: Interleukin 17 (IL-17) has a key role in inflammatory responses. Increased serum concentrations of IL-17 have been reported in patients with different types of cancer. Some studies suggest antitumor activity of IL-17 while others speak in favor of its association with poorer prognosis. The lack of data on IL-17 behavior in vivo hinders the efforts to clarify the exact role of IL-17 in breast cancer patients and precludes the usage of IL-17 as potential therapeutic target.

Methods: The study included 118 patients with early invasive breast cancer. The serum concentration of IL-17A was measured before surgery and during adjuvant treatment and compared with healthy controls. The correlation of serum IL-17A concentration and different clinical and pathological parameters, including IL-17A expression in the corresponding tumor tissue samples, was analyzed.

Results: Significantly higher serum concentrations of IL-17A were found in women with early breast cancer before surgery, but also during adjuvant treatment in comparison to healthy controls. No significant correlation to tumor tissue IL-17A expression was observed. There was a significant postoperative decrease of serum IL-17A concentrations even in patients with relatively lower preoperative values. A significant negative correlation was found between serum IL-17A concentrations and the tumor estrogen receptor expression.

Conclusion: The results suggest that the immune response in early breast cancer is mediated by IL-17A, particularly in triple-negative breast cancer. IL-17A-mediated inflammatory response subsides postoperatively, but IL-17A concentrations remain elevated compared to the values in healthy controls, even after the removal of the tumor.

• Ključne riječi (engleski): IL-17; breast cancer; cancer immunology; interleukin-17; tumor microenvironment; tumor-related inflammation
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Izvorni znanstveni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Frontiers in Oncology
• Brojčani podaci: vol. 13, 1171254
• e-ISSN: 2234-943X
• DOI: https://doi.org/10.3389/fonc.2023.1171254
• URN:NBN: urn:nbn:hr:105:252900
• Datum objave publikacije: 2023-06-23
• Projekt: Šifra: 108-1080058-0046; Naziv (hrvatski): KARCINOM DOJKE-MOLEKULARNE,GENETSKE I KLINIČKE KARAKTERISTIKE; Naziv (engleski): BREAST CANCER-MOLECULAR, GENETIC AND CLINICAL CHARACTERISTICS; Voditelj: Damir Vrbanec; Pravna nadležnost: Hrvatska; Financijer: Ministarstvo znanosti, obrazovanja i mladih Republike Hrvatske; Linija financiranja: zProjects
• URL dokumenta: https://www.frontiersin.org/articles/10.3389/fonc.2023.1171254/full
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2024-09-26 08:31:45